Accession Number:

AD1007015

Title:

Targeting Androgen Receptor in Breast Cancer: Enzalutamide as a Novel Breast Cancer Therapeutic

Descriptive Note:

Technical Report,15 Aug 2014,14 Aug 2015

Corporate Author:

Regents of the University of Colorado Aurora United States

Personal Author(s):

Report Date:

2015-09-01

Pagination or Media Count:

12.0

Abstract:

Enzalutamide has clinical activity in breast cancer as a single agent and in combination with exemestane. Activity is seen in both triple negative AR positive BC and also ER positive AR positive BC. Clinical data in Her2 positive AR positive BC is too immature to make conclusions. The proposed clinical trials for Years 3-5 appear to be justified based on clinical activity and the current preclinical data.

Descriptors:

Subject Categories:

Distribution Statement:

APPROVED FOR PUBLIC RELEASE